AbbVie Inc (ABBV) Q2 2026 Earnings Preview: What to Watch
AbbVie faces a critical Q2 earnings report as it balances Humira's decline with the growth of its new immunology portfolio.
The setup
AbbVie management recently updated its 2026 outlook to incorporate a $291 million pre-tax IPR&D and milestone expense. This adjustment resulted in a revised full-year 2026 adjusted diluted EPS guidance range of $13.91 to $14.11.
The market is currently weighing the impact of this charge against the long-term margin expansion potential of the firm's core assets. CEO Rob Michael has expressed confidence that the company will exceed peak consensus models for its primary growth drivers, Skyrizi and Rinvoq.
- Goldman Sachs maintains a Neutral rating with a $244 price target, citing limited room for error at current valuation levels.
- Cantor Fitzgerald holds an Overweight rating and a $265 target, emphasizing the long-term growth trajectory.
- Macro factors include ongoing pricing pressure in the drug manufacturing sector and potential regulatory scrutiny of international clinical trials.
Consensus numbers
Wall Street analysts have set a consensus EPS estimate of approximately $3.60 for the second quarter. Revenue expectations are centered around $16.78 billion.
The company has a track record of exceeding estimates, having posted EPS of $2.65 against an estimate of $2.59 in the most recent quarter ending April 2026.
- Q2 2026 EPS Estimate: $3.60
- Q2 2026 Revenue Estimate: $16.78 billion
- Q1 2026 Actual EPS: $2.65 vs $2.59 estimate
- Q4 2025 Actual EPS: $1.86 vs $1.77 estimate
- Q3 2025 Actual EPS: $2.71 vs $2.65 estimate
What we'll watch on the call
The primary focus for analysts remains the volume growth of Skyrizi and Rinvoq. Investors need to see if this growth is sufficient to offset both pricing headwinds and the continued erosion of Humira revenue.
The Aesthetics segment, including Botox and facial fillers, is under pressure to demonstrate a sustained recovery. Additionally, the Neuroscience segment, led by Vraylar, Qulipta, and Vyalev, is being monitored as a key pillar for long-term growth.
- Can volume growth in Skyrizi and Rinvoq continue to outpace pricing headwinds?
- How should investors interpret the $291 million IPR&D charge in the context of long-term margin expansion?
- Are there early signs of a meaningful recovery in the Aesthetics segment?
- Will currency fluctuations continue to provide a modest tailwind to global sales?
Fintwit's AI verdict
The quantitative models suggest a favorable outlook for the upcoming report, provided the core immunology assets maintain their current momentum. While the recent IPR&D charge created a slight downward drift in sentiment, the underlying fundamentals appear resilient.
Investors should weigh the potential for a beat against the current valuation, which leaves little margin for operational disappointment. The market will be looking for clear evidence that the growth engine is firing on all cylinders.